Ctrl

K

Margetuximab

Class
Targeted therapy
Subclass
Anti-HER2 monoclonal antibodies
Substance name
Margetuximab, margetuximab-cmkb
Brand names
Margenza®
Common formulations
Concentrate for injectable solution
Dosage and administration
Adults patients
Breast cancer in females • Metastatic, HER2+
•
15 mg/kg IV q3 weeks until disease progression or unacceptable toxicity
Breast cancer in females • HER2+, metastatic
•
15 mg/kg IV q3 weeks until disease progression or unacceptable toxicity
Indications for use
Labeled indications
Adults
•
Treatment of breast cancer in females (HER2+, metastatic)
•
Treatment of breast cancer in females (metastatic, HER2+)
Pregnancy and breastfeeding
Breastfeeding
Acceptable for use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Interactions
Drug(s)
Check Interactions
Reset

What did you think about this content?

Create free account

Sign up for free to access the full drug resource